Hip Fractures in Chile: Implications for Public Health Policy and Healthcare Delivery

February 12, 2024 updated by: maximiliano barahona vasquez, University of Chile
Hip fractures in individuals aged 60 and above pose significant challenges in terms of morbidity, mortality, and healthcare costs. While countries like the United Kingdom and Australia have optimized their healthcare systems for timely management of hip fractures, the situation in Chile presents distinct challenges due to its mixed healthcare system. This study aims to assess survival rates following hip fractures in Chile and identify associated risk factors using national databases from 2012 to 2018. A comprehensive analysis of 35,520 patients revealed that factors such as age, type of health insurance, access to surgery, and treatment in public hospitals significantly influence mortality rates after hip fractures. The study found that patients with hip fractures experience lower 5-year survival rates compared to the general population, particularly when affiliated with public insurance and treated in public institutions. Modifiable factors like delayed surgery and prolonged hospital stays contribute to increased mortality rates. The findings underscore the urgent need for optimized public health policies and healthcare delivery systems to enhance outcomes for hip fracture patients in Chile.Hip fractures in individuals aged 60 and above pose significant challenges in terms of morbidity, mortality, and healthcare costs. While countries like the United Kingdom and Australia have optimized their healthcare systems for timely management of hip fractures, the situation in Chile presents distinct challenges due to its mixed healthcare system. This study aims to assess survival rates following hip fractures in Chile and identify associated risk factors using national databases from 2012 to 2018.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

46380

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Region Metropolitana
      • Santiago, Region Metropolitana, Chile, 8380456
        • Hospital Clínico Universidad de Chile

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The chilean national database of hospital discharge and the chilean death registry from 2012 to 2018 were used. , The date of death was recorded for the 35,520 patients who had deceased; otherwise, they are classified as alive as of the current date. We remark that the national discharge and death databases use the same patient IDs, and therefore, we can easily identify those patients who have died during the period under analysis. We notice that we have used the hospital discharge database up to 2017 to have at least one year of follow-up for patients after a hip fracture.

Description

Inclusion Criteria:

All patients in the national database between 2012 and 2017 which his principal was hip fracture. Diagnoses are classified using the International Classification of Diseases, 10th Revision (ICD-10) codes. A search was conducted for codes S72.0 (head and neck fracture of the femur), S72.1 (pertrochanteric fracture), and S72.2 (subtrochanteric fracture of the femur).

Exclusion Criteria:

missing IDs ID with inconsistent socio-demographic information. Patients with primary diagnosis of hip fracture that underwent surgery but the national code surgery was not one of the following: : 2104128, 2104129, 2104131, 2104132, 2104135, 2104228, 2104229 and 2104231

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
hip fracture
patients that were diagnosed with a hip fracture between 2012 and 2017
access to surgery after hip fracture
public or private health care facility

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
survival after hip fracture
Time Frame: one to five years after the hip fracture
survival after hip fracture
one to five years after the hip fracture

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Susana Mondschein, PhD, University of Chile

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 10, 2023

Primary Completion (Actual)

March 10, 2023

Study Completion (Actual)

January 30, 2024

Study Registration Dates

First Submitted

February 12, 2024

First Submitted That Met QC Criteria

February 12, 2024

First Posted (Actual)

February 20, 2024

Study Record Updates

Last Update Posted (Actual)

February 20, 2024

Last Update Submitted That Met QC Criteria

February 12, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 101 (Other Identifier: Hamilton Integrated Research Ethics Board)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Both National regestries are free access, nevertheless, the raw data will be made available after publication.

IPD Sharing Time Frame

after publication, until 10 years.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hip Fractures

Clinical Trials on Access to surgery

Subscribe